1. Home
  2. LDI vs CTNM Comparison

LDI vs CTNM Comparison

Compare LDI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$1.42

Market Cap

587.6M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.73

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
CTNM
Founded
2010
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
587.6M
480.5M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
LDI
CTNM
Price
$1.42
$12.73
Analyst Decision
Sell
Buy
Analyst Count
3
4
Target Price
$3.00
$19.00
AVG Volume (30 Days)
1.8M
303.4K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.58
N/A
Revenue Next Year
$13.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$3.35
52 Week High
$5.05
$16.33

Technical Indicators

Market Signals
Indicator
LDI
CTNM
Relative Strength Index (RSI) 38.67 44.71
Support Level $1.31 $11.54
Resistance Level $1.96 $13.18
Average True Range (ATR) 0.08 0.87
MACD 0.02 0.02
Stochastic Oscillator 51.59 34.25

Price Performance

Historical Comparison
LDI
CTNM

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: